FVFlorian Visentin

Florian Visentin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Florian Visentin has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interleukin-18 binding protein protects against metabolic steatohepatitis

    by Emmanuel Somm, Yunju Jo, Elodie Perroud, Frédérique Ino, Karina Lindner, Baeki E. Kang, Christelle Veyrat-Durebex, Franck Bontems, Florian Visentin, Sébastien Fauteux-Daniel, et al.

    Background: Metabolic dysfunction–associated steatohepatitis (MASH) is a frequent consequence of Western diet consumption and liver steatosis. IL-18 binding protein (IL-18BP) limits the action of interleukin-18 (IL-18). Our work aims to study the unknown role of IL-18BP in MASH progression. Methods: We analyzed the liver transcriptome from MASH patients. We investigated cell-specific expressions of IL-18, IL-18BP, and IL-18 receptor in human and mouse liver. We studied the liver phenotype of Il18bp −/− mice on a high-fat/high-cholesterol (HFHC) diet. We administered an anti-IL-18 antibody in Il18bp −/− mice and in diet-induced wild-type (WT) MASH mice. We generated and studied double knock-out Il18bp −/− Ifng −/− mice. Results: IL-18BP expression is increased in the liver of patients and mouse models with MASH and positively correlates with fibrosis stages. On the HFHC diet, Il18bp −/− mice exhibit increased hepatic damage, inflammation, and fibrosis compared with WT mice. Treatment with anti-IL-18 antibody corrects liver defects in Il18bp −/− mice and ameliorates inflammation and fibrosis in diet-induced MASH mice, suggesting a translational treatment opportunity. Genetic deficiency in IFN-γ abrogates inflammation but not fibrosis in Il18bp −/− mice. Conclusions: IL-18BP has a role in limiting the progression of MASH, notably by reducing inflammation and fibrosis. Downstream IL-18 over-signaling, IFN-γ, mediates inflammation, but not fibrosis. Increasing IL-18BP levels represents a novel therapeutic perspective for patients affected by MASH.


  • Open Access

    Harnessing distinct tissue-resident immune niches via S100A9/TLR4 improves ketone, lipid, and glucose metabolism

    by Giulia Lucibello, Gloria Ursino, Pryscila D. S. Teixeira, Szabolcs Zahoran, Francesca Fanuele, Marinos Kallikourdis, Florian Visentin, Christelle Veyrat-Durebex, Ariane Widmer, Yibo Wu, et al.

    Immunometabolism contributes to the development of metabolic diseases. Yet, how certain metabolic disorders, such as insulin deficiency (ID), influence immune cell function is poorly understood. Here, we observe that ID rearranges the immune landscape of the liver, causing a decrease in T cells and an increase in Kupffer cells, accompanied by a shift in the transcriptome and polarization of the latter. Treating ID mice with the protein S100A9 rescues the polarization and lipid-related changes caused by ID in the KCs, and rescues hypertriglyceridemia and hyperketonemia in a TLR4-dependent manner. Additionally, S100A9 acts on other immune niches to increase glucose uptake in skeletal muscle, improving hyperglycemia. In summary, the S100A9-TLR4 axis is a new tool to harness immune cells for improving ID-related metabolic dysfunction.

  • Open Access

    17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells

    by Sandra Handgraaf, Rodolphe Dusaulcy, Florian Visentin, Jacques Philippe, Yvan Gosmain

    Clinical and experimental data indicate a beneficial effect of estrogens on energy and glucose homeostasis associated with improved insulin sensitivity and positive effects on insulin secretion. The aim of the study was to investigate the impact of estrogens on proglucagon-producing cells, pancreatic α cells, and enteroendocrine L cells. The consequences of sexual hormone deprivation were evaluated in ovariectomized mice (ovx). Ovx mice exhibited impaired glucose tolerance during oral glucose tolerance tests (OGTT), which was associated with decreased GLP-1 intestinal and pancreatic secretion and content, an effect that was reversed by estradiol (E 2 ) treatment. Indeed, E 2 increased oral glucose–induced GLP-1 secretion in vivo and GLP-1 secretion from primary culture of mouse and human α cells through the activation of all 3 estrogen receptors (ERs), whereas E 2 -induced GLP-1 secretion from mouse and human intestinal explants occurred only by ERβ activation. Underlying the implication of ERβ, its selective agonist WAY20070 was able to restore glucose tolerance in ovx mice at least partly through plasma GLP-1 increase. We conclude that E 2 directly controls both α- and L cells to increase GLP-1 secretion, in addition to its effects on insulin and glucagon secretion, highlighting the potential beneficial role of the estrogenic pathway and, more particularly, of ERβ agonists to prevent type 2 diabetes.